John Diener
Senior Vice President Tectonic Therapeutics
Project and Team leader with over 20 years of biotech and pharma experience focused on discovery and development of biologics including proteins, antibodies, and nucleic acids-based molecules. My disease area focus has been primarily in cardiometabolic and rare hematologic diseases. I currently lead the computational biology, antibody discovery and protein sciences groups at Tectonic Therapeutic.
Seminars
Thursday 30th April 2026
Engineering of a Long-Acting Relaxin for the Treatment of Pulmonary Hypertension
1:45 pm
- Using a biophysics-based approach to engineer a long-acting relaxin molecule for chronic therapy
- Showing that TX45 is effective in a rat model of severe pulmonary hypertension
- In parallel we used the well-established effects of relaxin on renal plasma flow in both rats in healthy volunteers to demonstrate the high degree of in vitro to in vivo correlation and the translatability of these effects for our optimized molecule
